{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:07:28Z","timestamp":1740175648843,"version":"3.37.3"},"reference-count":0,"publisher":"Maad Rayan Publishing Company","content-domain":{"domain":["apb.tbzmed.ac.ir"],"crossmark-restriction":false},"short-container-title":["Adv Pharm Bull"],"published-print":{"date-parts":[[2021,10,6]]},"abstract":"<jats:p>SARS-CoV2 is the causative organism of COVID-19. Since this disease is considered new and does not have an approved curative protocol, many researchers have tackled the possible options for COVID-19 prevention and therapeutic approaches. We address herein the phenomena of cytokine storm (the main cause of death) associating with the late stage of COVID19. Cytokine storm is undertaken in an attempt to provide information about its possible underlying causes, and to clarify some points that can be of value in guiding treatment practices for a clinical trial.<\/jats:p>","DOI":"10.34172\/apb.2022.067","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T07:48:25Z","timestamp":1634802505000},"update-policy":"https:\/\/doi.org\/10.34172\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Promising Adjunct Medicines in the Protocol of Covid-19 Clinical Trial"],"prefix":"10.34172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-1149","authenticated-orcid":true,"given":"Mona Mahmoud","family":"AbouSamra","sequence":"first","affiliation":[{"name":"Pharmaceutical Technology Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Cairo, 12622 Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheir Said","family":"Mansy","sequence":"additional","affiliation":[{"name":"Electron Microscopy Research Department, Theodor Bilharz Research Institute, Cairo, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"20123","published-online":{"date-parts":[[2021,10,6]]},"container-title":["Advanced Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/apb.tbzmed.ac.ir\/Inpress\/apb-32577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/apb.tbzmed.ac.ir\/Inpress\/apb-32577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:16:46Z","timestamp":1648707406000},"score":1,"resource":{"primary":{"URL":"https:\/\/apb.tbzmed.ac.ir\/Inpress\/apb-32577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.34172\/apb.2022.067","relation":{},"ISSN":["2228-5881","2251-7308"],"issn-type":[{"type":"print","value":"2228-5881"},{"type":"electronic","value":"2251-7308"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"Tabriz University of Medical Sciences","name":"journal_owner","label":"Journal Owner"},{"value":"Tabriz University of Medical Sciences","name":"journal_publisher","label":"Journal Publisher"},{"value":"2021-05-24","order":1,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}